Notes:
- S6C: Correct diagnosis. The implied Android rate (~22%) and the falsifiable prediction are useful. The "roughly 75%" confidence figure is exposed scoring and isn't backed by anything on the page.
- Y3E: Thorough. The point about local payment methods (Pix/UPI/boleto) is good, and so are the measurement-artifact check and the CEO script. The "close to neutral" revenue arithmetic is loose (0.75 x 1.22 is about -8.5%, and it mixes the price and bug effects), and the reply runs a bit long.
- P9I: Tight and correct. The undercounting mechanism, the BR/IN/MX iOS control and plotting against the rollout percentage are all strong. It dismisses cohort maturity ("doesn't explain a drop this large") without knowing the trial length.
- N2A: Most actionable. It covers the 3-day acknowledgement auto-refund and checking refund-timing clustering, RTDN logs and the billing diff, gives thresholds for the iOS US/UK/EU price read, treats the fix as urgent, and includes an explicit falsification clause. Slightly long.

```scores
judge,code,V1,V2,V3,V4,G1,G2,G3,total
J-A,S6C,6,6,6,6,6,4,5,39
J-A,Y3E,6,6,5,6,5,6,6,40
J-A,P9I,6,6,6,6,6,7,5,42
J-A,N2A,6,7,6,7,5,7,6,44
```

```ranking
judge,brief,order
J-A,brief-3,N2A P9I Y3E S6C
```
